Special Health Care Edition of The Wall Street Transcript
NEW YORK--(BUSINESS WIRE)--Dec. 22, 1998--The Wall Street Transcript has just made available a special 270-page Health Care edition produced for the December 14-16 ING Baring Furman Selz Health Care '98 Conference. Featuring interviews with eleven leading research analysts and CEOs or top management from 65 Health Care firms, this special issue offers an excellent current review of the sector for analysts, investors, and companies.
Highlights include:
1) Interviews with eleven leading analysts from ING Baring Furman Selz;
Biotechnology - Jonas Alsenas. Because biotech stocks have their biggest move in the three or four quarters leading up to their first profitable quarter, Alsenas asserts, "If you really want to maximize the bang for your buck, the key is to find the companies that are really about a year or so from turning profitable."
Contract Research Organizations - Ruby Holder. Advising investors to research companies before investing, Holder states, "Trials get cancelled all the time; it's part of the drug discovery process. You need to look at the company size, the company's client and project concentration, and have an understanding of each company's risk profile to determine the effect of a major contract being cancelled."
The Outlook for Health Care - Stephen Buell. Looking forward, Buell says, "I think that the pharmaceutical and medtech industries have just begun to leverage the three technologies that have been the key drivers of product innovation, namely high-speed computation, molecular biology and materials sciences. So I think that on the supply side, there is tremendous room for new product generation on a very long-term basis."
Assisted Living/Nursing Homes/Hospitals - Leslie Henshaw. Due in part to increasing consolidation opportunities, Henshaw states, "We believe that, at least over the next two-to-three-year window, the industry's larger players, which continue to have access to capital, offer fairly high visibility on 30-35% earnings growth."
HMOs & Managed Care Companies - Robert Hoehn. Looking ahead, Hoehn declares, "I believe the short-term outlook for managed care stocks is favorable. We upgraded a number of the managed care stocks in early September, and I think this upward trend that we've seen since then is going to continue right into the second quarter."
Health Care Information Services - Stephen DeNelsky. Counseling investors to take a "more company specific approach," DeNelsky says, "The quality of earnings between the various companies differs greatly, and I think that's primarily a result of many companies using acquisitions to fuel their growth."
Drug Discovery Technology - Paul Kelly. Emphasizing the importance of researching technological and business models, Kelly advises, "They can have the most fascinating technology in the world, but if it doesn't have a real market or a real route to tangible milestones to developing that market, then it should be more the stuff of hobby than investment."
Pharmaceutical & Specialty Pharmaceuticals - James Flynn. FDA policy changes, including fast tracking new drugs and approving direct-to-consumer advertising has helped the industry according to Flynn, who says, "That's having a direct impact on expanding in a number of different markets in a way that's very important for the industry and helping them perpetuate their current double-digit unit growth."
Medical Device & Technology Companies - Samuel Navarro. Because most medical technology breakthroughs and innovations come from small companies, Navarro proclaims, "The unspoken rule of "big-is-better" and "small-begets-breakthroughs" continues to exist."
Ear, Nose & Throat Industry - Joanne Wuensch. Highlighting growth opportunities for players in the sleep apnea market, Wuensch points out, "The market opportunity is enormous; the sleep apnea market is only about $250-300 million right now. Only about 4% of the 20 million people in the United States who have OSA are diagnosed."
Orthopedic, Cardiac Surgery & Diabetes - Kevin Kotler. Emerging technologies in diabetes treatment offer opportunity, Kotler declares, "Most of these new technologies are under development or being evaluated in the clinic. Here again, MiniMed (MNMD) should lead the field, as it had developed the first continuous glucose sensor product and is currently awaiting news from the FDA regarding the review of its PMA application."
2) CEOs or top executives from the following companies are interviewed in this special 270-page Health Care issue: Alternate Living Services (ALI), American Medical Security Group (NYSE:AMZ), Applied Analytical Industries (Nasdaq:AAII), Aradigm Corp. (Nasdaq:ARDM), Arrow International (Nasdaq:ARRO), Axys Pharmaceuticals (Nasdaq:AXPH), BioChem Pharma (Nasdaq:BCHE), Bionx Implants (Nasdaq:BINX), Brookdale Living Communities (Nasdaq:BLCI), CardioThoracic Systems (Nasdaq:CTSI), Celgene (Nasdaq:CELG), Cell Therapeutics (Nasdaq:CTIC), Centocor (Nasdaq:CNTO), Cephalon (Nasdaq:CEPH), COR Therapeutics (Nasdaq:CORR), Covance (NYSE:CVD), C.R.Bard, Inc. (NYSE:BCR), Cubist Pharmaceuticals (Nasdaq:CBST), Chronimed (Nasdaq:CHMD), CV Therepeutics (Nasdaq:CVTX), Dura Pharmaceuticals (Nasdaq:DURA), Emisphere Technologies (Nasdaq:EMIS), Enzon (Nasdaq:ENZN), Forest Laboratories (AMEX:FRX), Foundation Health Systems (NYSE:FHS), Gene Logic (Nasdaq:GLGC), Genentech (NYSE:GNE), Genzyme (Nasdaq:GENZ), Gilead Science (Nasdaq:GILD), Guidant (NYSE:GDT), Healthplan Services (NYSE:HPS), Human Genome Sciences (Nasdaq:HGSI), IDEC Pharmaceuticals (Nasdaq:IDPH), ILEX Oncology (Nasdaq:ILXO), IMPATH (IMPH), IVAX Corp (AMEX:IVX), Kendle International (Nasdaq:KNDL), Leukosite (Nasdaq:LKST), Liposome Company (Nasdaq:LIPO), Lynx Therapeutics (Nasdaq:LYNX), Medaphis (Nasdaq:MEDA), MedQuist (Nasdaq:MEDQ), Micro Therapeutics (Nasdaq:MTIX), Millenium Pharmaceuticals (Nasdaq:MLNM), MiniMed (Nasdaq:MNMD), Molecular Devices Corp. (Nasdaq:MDCC), Myriad Genetics (Nasdaq:MYGN), New American Healthcare (NYSE:NAH), North American Vaccine (AMEX:NVX), NPS Pharmaceuticals (Nasdaq:NPSP), ONYX Pharmaceuticals (Nasdaq:ONXX), Organogenesis (AMEX:ORG), Perclose (Nasdaq:PERC), Pharmacopeia (Nasdaq:PCOP), PMP Corp. (Nasdaq:PMRP), Quintiles Transnational (Nasdaq:QTRN), Quorum Health Group (Nasdaq:QHGI), Roberts Pharmaceuticals (AMEX:RPC), Sierra Health Services (NYSE:SIE), Trigon Healthcare (NYSE:TGH), Trimeris (Nasdaq:TRMS), Universal Health Services (NYSE:UHS), U.S. Bioscience (AMEX:UBS), Vysis (Nasdaq:VYSI), and Xomed Surgical Products (Nasdaq:XOMD). These are in-depth discussions (average 3,000 words) with the people leading these firms, talking about their companies; the key trends they see in their markets; the opportunities they face and their key concerns; specific goals they are setting for their organization; and the outlook for investors.
For information on how to obtain a copy of this issue, see twst.com or call (212) 952 - 7433. The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.
The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 35 years. The Transcript publishes industry roundtables and interviews with Wall Street analysts, money managers, and company CEOs, and is read by top money managers, brokers, and individual investors.
CONTACT:
The Wall Street Transcript
twst.com
800/246-7673 |
